From Remedy to Therapy: Confronting the Bioavailability Bottleneck in Ganoderma lucidum Translational Research

Background/Objectives: For over two millennia, Ganoderma lucidum has served as a traditional remedy, yet its translation into evidence-based therapy remains stymied by a persistent obstacle. Potent in vitro activities consistently fail to translate in vivo, a shortfall rooted in the poor systemic bioavailability of its signature triterpenoids and polysaccharides. We contend that the defining hurdle is no longer compound discovery but whether emerging formulation technologies genuinely overcome these barriers or merely sidestep them in ways that obscure the underlying physiology. Methods: We construct a structure–activity–formulation (SAF) prioritization framework. We critically survey a broad spectrum of delivery platforms—including lipid-based, polymeric, micellar, tellurium nanorod, and G. lucidum-derived vesicular systems—against their demonstrated capacity to improve oral exposure. Clinical assessments and regulatory considerations are integrated to anchor the analysis in translational reality. Results: Bioavailability has been systematically treated as a post hoc variable, even though the very structural features conferring bioactivity impose the steepest systemic barriers. To date, no G. lucidum nanoformulation has advanced to human trials, and the regulatory terrain for these complex natural-product nanomedicines remains uncharted. We distill three experimentally tractable propositions—testing lipid-mediated absorption, triple-helix conformational dependency, and co-delivery synergy—that offer discrete entry points for rigorous investigation. Conclusions: We argue that the field must pivot decisively from descriptive cataloging to hypothesis-driven, comparative investigation, anchored by reference-material standardization and proactive regulatory dialogue. Confronting the bioavailability bottleneck as a primary design parameter—rather than an ancillary nuisance—represents the most credible route from historical remedy to evidence-based therapeutic.